Sorafenib, Pazopanib, and Sunitinib, all known inhibitors of multiple tyrosine protein kinases and receptor tyrosine kinases, have been reported to reduce tumor vascularization, trigger cancer cells and, thus, promote tumor shrinkage [120, 121, 122]. This evidence concerns the gene NTRK1 and neoplasm.